Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Imclone systems (IMCL) -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (1931)	1/26/2002 1:30:05 PM
From: hmpa	Read Replies (1) \| Respond to of 2515

George, what I mean is that in the CNN interview (URL in one of the messages preceding mine) the Sterling analyst claimed they knew back in August IMCL study is flawed. It seems to me it is difficult to reconcile this preeminent "knowledge" in August and "sell" rating 2 months later with target of 42 which clearly could have been achieved on trading technicals alone. My impression about Sterling analysis is that they look which stock looks "toppy" technically and then try to make up some sort of justification for their call. Sometimes this scattershot works - like in CBST - I strongly doubt Sterling had any clue of poor results in yet unblinded East European trials; nevertheless they declared it a sell.